Search

Your search keyword '"Wei, Andrew"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Wei, Andrew" Remove constraint Author: "Wei, Andrew" Database Springer Nature Journals Remove constraint Database: Springer Nature Journals
27 results on '"Wei, Andrew"'

Search Results

2. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?

3. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

6. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

8. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

9. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

10. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

13. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

14. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

16. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

17. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

18. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

19. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

20. Genomic subtyping and therapeutic targeting of acute erythroleukemia

Catalog

Books, media, physical & digital resources